Skip to content

Artificial Intelligence in Large-scale Breast Cancer Screening

Artificial Intelligence in a Population-based Breast Cancer Screening - the Prospective Clinical Trial ScreenTrust CAD

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04778670
Acronym
ScreenTrustCAD
Enrollment
55579
Registered
2021-03-03
Start date
2021-04-01
Completion date
2024-12-31
Last updated
2023-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasm Female

Keywords

Artificial Intelligence, Breast Cancer, Mammography, Screening

Brief summary

This is a prospective clinical trial following a paired screen-positive design, with the aims to assess the performance of an artificial intelligence (AI) computer-aided detection (CAD) algorithm as an independent reader, in addition to two radiologists, of screening mammograms in a true screening population. Since all decisions by individual readers will be recorded, it is possible to determine what the outcome would have been had one or two of the readers not been allowed to assess images, and to determine what the outcome would have been had the recall decision been performed by consensus decision (actual) compared to single reader arbitration of discordant cases.

Interventions

DIAGNOSTIC_TESTAI CAD

The Lunit INSIGHT MMG will be used as the AI CAD in our study. Initially, version 1.6.1.1 will be installed. The software version will be continuously updated with subsequent software releases, after confirming in a historic calibration dataset that the performance is improved. The operating point will be set based on a historic calibration dataset to attain a joint sensitivity of breast cancer detection of AI and first reader which is 2% higher than for first and second reader.

DIAGNOSTIC_TESTRadiologist reading

Standard of care, each radiologist will assess the mammography examination, making a binary flagging decision (flag the examination to continue to consensus discussion, or not)

Sponsors

Capio Sankt Görans Hospital
CollaboratorOTHER
Lunit Inc.
CollaboratorINDUSTRY
Karolinska Institutet
CollaboratorOTHER
Karolinska University Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
TRIPLE (Subject, Caregiver, Investigator)

Masking description

Positive disease status is ascertained by pathology-verified breast cancer. Disease status is not known to any of the actors (except for the outcomes assessor by necessity). AI decision is not known by the care provider radiologists until they have made their decisions. In the subsequent consensus discussion where a decision is made to recall or not to recall a woman, the AI decision is known. After AI decision has been recorded and outcomes have been assessed, the investigators will have full information on outcomes and AI decisions.

Intervention model description

This is a prospective clinical trial following a paired screen-positive design (Pepe, Alonzo; 2001), with the aims to assess the performance of an AI algorithm combined with radiologists(s) compared to standard-of-care being two radiologists assessing screening mammograms in a true screening population. Since all decisions by individual readers will be recorded, it is possible to determine what the outcome would have been had one or two of the readers not been allowed to assess images, and to determine what the outcome would have been had the recall decision been performed by consensus decision (actual) compared to single reader arbitration of discordant cases.

Eligibility

Sex/Gender
FEMALE
Age
40 Years to 74 Years
Healthy volunteers
No

Inclusion criteria

* Participants in regular population-based breast cancer screening at Capio St Göran Hospital

Exclusion criteria

* Incomplete exam (complete exam: mediolateral oblique and craniocaudal images of Left and Right breast) * Breast implant * Complete mastectomy (excluded from screening positive group) * Participant in surveillance program for prior breast cancer

Design outcomes

Primary

MeasureTime frameDescription
Incident breast cancerAt ScreeningBreast cancer diagnosis by pathologist

Secondary

MeasureTime frameDescription
Reader flaggingAt screeningRadiologist or AICAD assessing the mammograms as suspicious or not suspicious for malignancy
Consensus recallAt screeningA decision by the consensus discussion to recall the woman for further work-up
Tissue samplingAt screeningBiopsy or fine needle aspiration performed
Process failureAt screeningFailure of the AI CAD software to generate AI scores

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026